Objective The aim of the study was to evaluate the effect of valsartan/amlodipine combination on insulin sensitivity in overweight-obese hypertensive patients. 
Introduction
It is widely accepted that excess weight and hypertension are closely related; the prevalence of elevated blood pressure increases progressively with increasing body mass index (BMI) and hypertension is about 6 times more frequent in obese than in lean subjects (1, 2) . One possible pathogenetic link between obesity and hypertension is insulin resistance with consequent hyperinsulinemia (3, 4) . Insulin resistance is commonly associated with obesity and is considered to increase blood pressure through renin-angiotensin system activation, sympathetic nervous system stimulation and vascular muscle cell proliferation (5, 6) . The clustering of insulin resistance, obesity and hypertension, which frequently coexist with other metabolic risk factors, is associated with an increase in cardiovascular morbidity and mortality (3) .
Although the current guidelines do not give specific recommendations for antihypertensive therapy of obese hypertensive patients, the need to improve the global risk profile in these high risk patients involves optimal pharmacological treatment of obesity hypertension that requires antihypertensive drugs that do not worsen and possibly improve insulin resistance and associated metabolic disturbances, beyond lowering blood pressure (BP) levels (7, 8) . Furthermore, since the response rates to antihypertensive drug therapy are notoriously low in overweight-obese patients (9, 10) , two or more antihypertensive agents are requested to reach the BP goal of <140/90 mmHg in these patients.
Most data from the literature indicate that diuretics and beta-blockers reduce insulin sensitivity and increase lipid levels (11, 12) ; calcium channel blockers (CCB) are generally considered to be metabolically neutral (13) , although some studies have indicated a positive impact on insulin sensitivity (14, 15) (11, 12, (16) (17) (18) 
. Blockade of the renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) increases insulin sensitivity and decreases the risk for developing type 2 diabetes

Patients and Methods
This was a prospective, randomized, open-label, blindedendpoint (PROBE) (20), crossover study.
Study population
The study population 
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Ethics
The study protocol was approved by the local Ethical Committee and written informed consent was obtained from each patient at the time of screening. 
Statistical analysis
Data are given as means ± SD. The statistical analysis of the data was performed by the statistical analysis software (SAS) system, version 6.12 (SAS Institute, Inc., Cary, NC, USA). For SBP and DBP, the treatment effect was evaluated by PROC GLM; variability sources considered were treatment and patients. Continuous variables were compared by analysis of variance (ANOVA). The statistical significance of the independent effects of treatments on the other variables was determined using analysis of covariance (AN-
COVA
meta-analysis suggested that antihypertensive treatment with CCB is associated with lower rates of new-onset diabetes mellitus compared to diuretics and beta-blockers (26). Two main mechanisms have been proposed for the increase of insulin sensitivity with CCB. First, these agents produce vasodilation and enhance blood flow to skeletal muscle; this may increase insulin and glucose delivery and enhance the nonoxidative pathways of glucose utilization (27). Secondly, CCB may increase insulin sensitivity at the cellular level, by decreasing the cytosolic free calcium concentrations (28). In the present study a weak but significant positive relationship between the GIR and the DBP changes was found with amlodipine monotherapy, which suggests a role of BP lowering in amlodipine mediated increase in insulin sensitivity. Although some controversial data have been initially reported in the literature, with some studies showing no effect on insulin sensitivity (29-31), current opinion is that ARB exert a positive influence on insulin sensitivity, particularly in patients with insulin resistance (32, 33). Mechanisms by
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which ARB improve insulin sensitivity are still debated. 
They may include increased glucose uptake in skeletal muscle via increased glucose and insulin delivery due to their vasodilatory effect. However, valsartan has been shown to be associated with lower rates of new onset diabetes mellitus compared to amlodipine in the VALUE study (34), which suggested that blockade of the RAS affected glucose metabolism through mechanisms other than the vascular vasodilating and BP lowering effects alone. Possible alternative explanations include the following: a) enhancement of insulin release by the pancreatic betacells through increased local blood supply (35); in addition to reducing the vasoconstrictive effect of angiotensin II on the vasculature of the endocrine pancreas, ARB may also prevent angiotensin II mediated fibrotic or other degenerative changes that could compromise beta-cell function (36); b) stimulation of the insulin signal cascade: the molecular basis of insulin resistance involves defects in several steps of the signalling pathway, including serine phosphorilation of the insulin receptor (IRS), degradation of IRS protein and altered activity of phosphoprotein phosphatases. In obese Zucker rats, an animal model of the human metabolic syndrome, an administration of an ARB enhances insulin signalling through a reduction in insulin receptor Ser994 phosphorylation (37) and increased GLUT4 protein expression (38); c) improvement of glucose homeostasis at the cellular level through agonistic interaction with peroxisome proliferator activated receptor (PPR)-gamma (39); d) increase in plasma adiponectin levels: adiponectin is an adipocyte derived insulin sensitizer with anti-inflammatory and antiatherogenic functions whose levels are negatively correlated with insulin resistance (40). In some clinical studies with ARB, adiponectin levels, which are typically low in obese patients, increased in parallel to the improvement in insulin resistance (41, 42). RAS blockade might increase adiponectin levels by suppressing tumor necrosis factor (TNF)-alfa synthesis (43), by preventing oxidative stress (44) or by increasing adipogenesis and adipocyte differentiation resulting in greater adiponectin production (45); e) increase in serum levels of insulin-like growth factor (IGF)-1, which plays an important role in the regulation
